ArticleBiomacromolecules2026
Reining in Multidrug Resistance Protein 1 via Binding Its Flexible Interdomain Linker with Sequence-Selective Peptide-Binding Nanoparticles.
Article in Biomacromolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overexpressed ATP-binding cassette (ABC) transporters, such as multidrug resistance protein 1 (MRP1) encoded by ABCC1, are responsible for multidrug resistance in anticancer treatment due to their abilities to prevent drugs from reaching their lethal intracellular concentrations. Similar overexpression of drug efflux pumps is a major contributor to antimicrobial resistance seen in bacteria. We report sequence-selective, molecularly imprinted nanoparticles (MINPs) targeting MRP1 in human cancer cells. These nanoparticles mask different segments of the long, flexible linker connecting NBD1 (nucleotide-binding domain 1) and TMD2 (transmembrane domain 2) of MRP1. Binding of the protein near the inner membrane interface is found to strongly inhibit the function of the efflux pump and sensitize Dox-resistant cancer cells to the drug, reducing its IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.